Key Points Question What is the serologic response to the BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis? Findings In this cohort study of 142 patients receiving hemodialysis, humoral response was compared in 66 patients sampled 28 days after receipt of 1 dose of vaccine with 76 patients who received 2 doses of vaccine sampled 14 days after the second dose. Among those receiving 1 dose, 6% had antireceptor binding domain response above the median level of convalescent serum vs 41% of those who received 2 doses at 1 week, increasing to 60% by 2 weeks. Meaning The findings of this study suggest that, given that patients receiving hemodialysis appeared to exhibit a poor humoral response to a single dose of BNT162b2 vaccine, the second dose should not be delayed. Importance Patients undergoing hemodialysis have a high mortality rate associated with COVID-19, and this patient population often has a poor response to vaccinations. Randomized clinical trials for COVID-19 vaccines included few patients with kidney disease; therefore, vaccine immunogenicity is uncertain in this population. Objective To evaluate the SARS-CoV-2 antibody response in patients undergoing chronic hemodialysis following 1 vs 2 doses of BNT162b2 COVID-19 vaccination compared with health care workers serving as controls and convalescent serum. Design, Setting, and Participants A prospective, single-center cohort study was conducted between February 2 and April 17, 2021, in Toronto, Ontario, Canada. Participants included 142 patients receiving in-center hemodialysis and 35 health care worker controls. Exposures BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Main Outcomes and Measures SARS-CoV-2 IgG antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD), and nucleocapsid protein (anti-NP). Results Among the 142 participants undergoing maintenance hemodialysis, 94 (66%) were men; median age was 72 (interquartile range, 62-79) years. SARS-CoV-2 IgG antibodies were measured in 66 patients receiving 1 vaccine dose following a public health policy change, 76 patients receiving 2 vaccine doses, and 35 health care workers receiving 2 vaccine doses. Detectable anti-NP suggestive of natural SARS-CoV-2 infection was detected in 15 of 142 (11%) patients at baseline, and only 3 patients had prior COVID-19 confirmed by reverse transcriptase polymerase chain reaction testing. Two additional patients contracted COVID-19 after receiving 2 doses of vaccine. In 66 patients receiving a single BNT162b2 dose, seroconversion occurred in 53 (80%) for anti-spike and 36 (55%) for anti-RBD by 28 days postdose, but a robust response, defined by reaching the median levels of antibodies in convalescent serum from COVID-19 survivors, was noted in only 15 patients (23%) for anti-spike and 4 (6%) for anti-RBD in convalescent serum from COVID-19 survivors. In patients receiving 2 doses of BNT162b2 vaccine, seroconversion occurred in 69 of 72 (96%) for anti-spike and 63 of 72 (88%) for anti-RBD by 2 weeks following the second dose and median convalescent serum levels were reached in 52 of 72 patients (72%) for anti-spike and 43 of 72 (60%) for anti-RBD. In contrast, all 35 health care workers exceeded the median level of anti-spike and anti-RBD found in convalescent serum 2 to 4 weeks after the second dose. Conclusions and Relevance This study suggests poor immunogenicity 28 days following a single dose of BNT162b2 vaccine in the hemodialysis population, supporting adherence to recommended vaccination schedules and avoiding delay of the second dose in these at-risk individuals. This cohort study examines the immune response of patients receiving maintenance hemodialysis to vaccination with 1 vs 2 doses of the BNT162b2 vaccine.
【초록키워드】 COVID-19, public health, Vaccine, BNT162b2 vaccine, COVID-19 vaccine, immune response, vaccination, vaccine doses, clinical trial, Health care, SARS-COV-2 infection, health care workers, Antibody Response, Health policy, Spike protein, nucleocapsid protein, cohort study, Receptor binding domain, kidney, vaccine dose, BNT162b2, Pfizer, polymerase chain reaction, COVID-19 vaccines, Health, Seroconversion, Hemodialysis, Humoral response, Survivors, COVID-19 vaccination, IgG antibodies, SARS-CoV-2 IgG antibody, Patient, Control, Kidney disease, Health care worker, randomized clinical trials, Canada, convalescent serum, Care, Pfizer-BioNTech, SARS-CoV-2 IgG, Anti-spike, single dose, Serologic response, Vaccinations, dose, exposure, Maintenance hemodialysis, Chronic hemodialysis, anti-RBD, vaccine immunogenicity, humoral, reverse transcriptase, Chain Reaction, interquartile range, second dose, median age, SARS-CoV-2 IgG antibodies, measure, single-center, center, participant, receipt, binding domain, Toronto, finding, high mortality rate, transcriptase, patient population, reverse transcriptase polymerase chain reaction testing, vaccination schedule, objective, controls, setting, polymerase chain, robust, Result, defined, evaluate, occurred, conducted, receiving, median, the spike protein, reached, individuals, Importance, were measured, exceeded, baseline, levels of antibody, of BNT162b2, Point, Relevance, the median, the SARS-CoV-2, with COVID-19, 【제목키워드】 response, the SARS-CoV-2,